Agenus Inc. reported revenue, including non-cash royalties, of $30.2 million in Q3 2025 and $80.0 million year-to-date, compared to $76.6 million year-to-date in 2024. The company recorded an operating loss of $4.5 million for the quarter and $34.6 million year-to-date, an improvement from a $94.6 million operating loss year-to-date in 2024. Net income for Q3 2025 was $63.9 million, with year-to-date net income of $7.5 million, versus a net loss of $185.5 million year-to-date in 2024. Basic earnings per share were $2.00 for the quarter and $0.37 year-to-date, compared to a loss of $8.65 per share in the previous year. Cash used in operations was $14.7 million in Q3 and $60.6 million year-to-date, down from $129.7 million in 2024. Key business developments included the launch of the global Phase 3 BATTMAN trial, government-funded reimbursed access for botensilimab plus balstilimab in France, and survival data presented at ESMO across more than 400 patients with over five refractory cancers. Additionally, the company announced a $10 million bridge facility agreement with Zydus and the deconsolidation of MiNK, resulting in a $100.9 million gain.